
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Anaheim, Calif. - The wave of the future for lesion removal maybe in vivo confocal microscopy-oriented cryosurgery, William Abramovits,M.D., said at Academy `01.